RPN-002 adenomyosis trial initiation
ReproNovo separately develops nolasiban for adenomyosis. This is a distinct indication from embryo-transfer support, despite the shared molecule.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Private-company classification explicitly supported by ReproNovo’s October 5, 2026 announcement; recheck before activation.
- The source states development intent, not a fixed clinical start date; confirm the relevant registry and authorized formulation.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Indication-development candidate — trial date unconfirmed
Company context
An official company source identifies the company as privately held. This is source-reported context, not independent legal-registry verification; recheck ownership, listing and acquisition status before any market listing.
Potential outcome market
Will a participant be dosed in a registered RPN-002 interventional adenomyosis trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.